Last reviewed 2026-04-19 · How we verify

Menorrhagia

Approved treatments

• Micronor · Johnson & Johnson
  ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects.
• Noretynodrel · Pfizer
• Orgovyx · MYOVANT SCIENCES
  Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors.
• Menstridyl
  Menstridyl works by blocking the action of cortisol, a hormone involved in the menstrual cycle.
• Jadelle · Fdn Consumer
  Jadelle works by binding to the progesterone receptor, which helps to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.
• Cyklokapron · Exela Pharma
  Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis.
• Meclofenamate
• Norinyl 1+50 28-Day
• Amchafibrin · Fundación Pública Andaluza Progreso y Salud
• transamin · Erzincan Military Hospital
• Meclofenamate · Memorial Sloan Kettering Cancer Center

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Menorrhagia patent landscape — cliff calendar, originator estates, attackable patents
• Menorrhagia treatment landscape brief
• Menorrhagia treatment updates RSS

Frequently asked questions about Menorrhagia

Related

• Treatment landscape: Menorrhagia patent cliff · Menorrhagia CI report
• Treatment: Micronor · Johnson & Johnson
• Treatment: Noretynodrel · Pfizer
• Treatment: Orgovyx · MYOVANT SCIENCES
• Treatment: Menstridyl
• Treatment: Jadelle · Fdn Consumer
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing